 The Report provides newly researched company profiles and competitive intelligence on 22 leading OTC producers (see full list below) operating in 8 key markets: Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, Venezuela.
This is a time of strong potential, but also great challenges, in the Americas’ OTC market as sales are primed to exceed US$10bn by 2013. The embedded culture of self-medication in states such as Argentina and Peru will drive double-digit growth. However, OTC sales expansion elsewhere – not least Mexico and Canada - will be dampened by increased health insurance coverage, highlighting the broader threat faced by prescription drugs marketing and sales.
The Americas' Leading OTC Medicine Markets features BMI's independent 5-year industry forecasts for each market to end-2012. Crucially, our long term views are founded upon our unique Business Environment Rating – a numerically-based risk-reward evaluation of the competitiveness of the regulatory and business operating environment for each of the 8 OTC markets, a vital tool for benchmarking both the rewards available in each state and the risks of market entry.
Rapid market expansion WILL occur. BMI forecasts that OTC sales will expand by 5.3% annually in US dollar terms between 2008-2012 to US$9.98bn, driven by region-wide trends of increased health awareness, self-medication and broader economic growth. Growth will be fastest in states where significant sections of the population have previously been unable to afford healthcare.
But economic growth risks abound. There is a strong correlation between OTC sales growth and economic expansion and, consequently, the US recession poses a significant short-term risk. However, the rapid commodities-fuelled expansion of many regional states – notably Chile, Peru and Venezuela – indicates strong potential in states where health insurance coverage – and thus a strong prescription market – is currently limited.
Furthermore, the regulatory environment is key. As ever, understanding the regulatory environment is vital. While Argentina actively encourages OTC sales, fears over the prevalence of self-medication in Brazil could curtail OTC availability, a scenario likely to recur in Mexico, where there is pressure to ban sales of OTCs in kiosks and supermarkets. A clear industry and company-specific strategy, supported by competitive pricing and responsive advertising, is key to building market share.
Key Benefits of the Report
Identify and evaluate the scale of growth opportunities across 8 key markets for OTC producers – including small, growing and little understood markets
Benchmark competitors and peers in each market using recently researched company profiles, featuring latest intelligence on 22 OTC companies, analysing competitive positioning, opportunities, risks and strategies of each company
Benchmark your own views and forecasts for market performance against BMI's independent 5-year industry forecasts for OTC drugs
Use BMI's country-comparative business environment ratings to assess the operating risks, opportunities and key factors impacting corporate profitability in each of the 8 markets covered
Executives who will benefit most from this Report:
Strategists – Gain an insight into the commercial opportunities available in the Americas' OTC market, using our clearly-explained medium-term economic forecasts (2008-2012) to benchmark your own growth projections.
Risk Managers – Discover the key Industry, Political, Economic and Operational risks facing companies in these rapidly developing states, and exploit BMI's quantitatively-based risk assessment model to stress-test your own assumptions.
Country Managers - Gain an insight into the country-specific growth trajectories and the key strengths of your clients and competitors.
Financial Planners – Critically evaluate the assumptions underpinning your medium-term financial projections using BMI's growth projections for the future direction and value of the currency and key domestic interest rates; the principal determinant of business investment and consumer spending growth.
List of 22 leading OTC companies profiled in The Americas' Leading OTC Medicine Markets:
Argentina (Novartis, GlaxoSmithKline, Boehringer Ingelheim)
Brazil (Sanofi-Aventis, Novartis, Sigma, Medley)
Canada (Novartis)
Chile(Laboratorios Chile, Laboratorios Andrómaco, Laboratorios Maver)
Colombia (GlaxoSmithKline, Novartis, Sanofi-Aventis, Lafrancol)
Mexico(Sanofi-Aventis, Bayer, Liomont)
Peru (Farmaindustria, Unimed)
Venezuela (Laboratorios Elmor, Grupo Farma)
|
